Recently, anti-CD123 therapeutic strategies, such as CD123 specific antibody and CD123-targeted chimeric antigen receptor (CAR) T cells, have been developed in AML treatment (16, 17). This evidence concerns the gene IL3RA and acute myeloid leukemia.